{"nctId":"NCT00539981","briefTitle":"Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","startDateStruct":{"date":"2007-09-15","type":"ACTUAL"},"conditions":["Influenza"],"count":4648,"armGroups":[{"label":"FluBlok (Lots A, B, C)","type":"EXPERIMENTAL","interventionNames":["Biological: FluBlok®"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo"]}],"interventions":[{"name":"FluBlok®","otherNames":["rHA Trivalent Recombinant Hemagglutinin Influenza Vaccine"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy adult aged 18-49 years.\n* Provided informed consent prior to any study procedures.\n* Able to comply with all study procedures.\n* Available for follow-up for the duration of the influenza season.\n* Women of child-bearing potential must have had a negative urine pregnancy test at the time of randomization and must be willing to use an adequate form of contraception (includes abstinence, condom with spermicide, licensed hormonal contraceptive, intrauterine device \\[IUD\\], monogamous relationship with a vasectomized partner) during the course of the study.\n\nExclusion Criteria:\n\n* Long-term use of oral steroids, parenteral steroids, or high-dose inhaled steroids (greater than \\[\\>\\] 800 mcg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (Nasal and topical steroids were allowed).\n* Presence of high-risk conditions or other characteristics were considered to be indication for influenza vaccination, as defined by the Advisory Committee on Immunization Practices.\n* Acute febrile illness (defined as having a temperature greater than or equal to \\[\\>=\\]100 degrees Fahrenheit) or upper respiratory tract illness within 72 hours of vaccination. Participants with acute febrile illness were rescheduled after fever resolved.\n* Use of experimental vaccines or any influenza vaccine other than FluBlOk after May 31st 2007 for the 2008 Southern Hemisphere or 2007 to 2008 Northern hemisphere epidemic seasons.\n* Immunosuppression as a result of an underlying illness or treatment, or used anticancer chemotherapy or radiation therapy within the preceding 36 months.\n* Any malignancy diagnosed or treated actively during the past five (5) years, with two (2) exceptions. Participant with any history of lymphoproliferative disorder were excluded. However, participants with a history of localized non-melanotic skin cancer were eligible.\n* Receipt of any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrollment in this study.\n* Receipt of an experimental agent (vaccine, drug, biologic, device, blood product or medication) within 1 month prior to enrollment in this study, or expected to receive an experimental agent during study period.\n* Receipt of parenteral immunoglobulin or other blood product within the three months prior to study vaccination.\n* Major psychiatric diagnosis including schizophrenia, bipolar disease or other major depression, or any diagnosis of dementia or associated concomitant medications (e.g., Aricept) used for treating dementia.\n* Known active human immunodeficiency virus, hepatitis B, or hepatitis C infection.\n* History of alcohol or drug abuse in the last 5 years.\n* Not available for three or more consecutive weeks during flu surveillance period.\n* Any acute or chronic condition that, in the opinion of the investigator, would render vaccination unsafe or interfere with the evaluation of responses or render the participant unable to meet the requirements of the protocol.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"49 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Reporting Solicited Injection Site (Local) Reactions","description":"Solicited reaction (reactogenicity event) was an adverse event (AE) that was pre-listed in electronic case report form(eCRF), considered to be related to vaccination and recorded by participant by means of memory aid. Injection sites reaction included pain,bruising,redness,swelling. Pain and bruising:Grade0: didn't have it at all; Grade1: noticed it, but it didn't interfere with usual activities at all; Grade2: had it, and it was bad enough to prevent a significant part of usual activities; Grade3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine, Redness and swelling: participants measured largest diameter of any injection site reaction and grade them from 0 to 3, where Grade0: measured less than(\\<)10 milliliters(mm); Grade1: larger than or equal to(\\>=) 10mm and \\<20mm; Grade 2: \\>=20mm and \\<50mm; Grade3: \\>=50mm. Participants with multiple symptoms in same category were counted once per category using symptom with maximum grade","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1421","spread":null},{"groupId":"OG001","value":"2050","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"797","spread":null},{"groupId":"OG001","value":"177","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2197","spread":null},{"groupId":"OG001","value":"2172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2181","spread":null},{"groupId":"OG001","value":"2184","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2195","spread":null},{"groupId":"OG001","value":"2189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Solicited Systemic Reactions","description":"Solicited reaction (reactogenicity event) was an AE that was pre-listed in eCRF, considered to be related to vaccination recorded by the participant by means of a memory aid between the day of vaccination (Day 0) and Day 7 post vaccination. Systemic events included fever, fatigue, shivering, joint pain, muscle pain, headache, and nausea. Fever: \\>=100.4 degree Fahrenheit (ºF) to \\<101.1ºF; \\>=101.2ºF to \\<102.2ºF; \\>=102.2ºF; Fatigue, shivering, joint pain, muscle pain, headache and nausea: Grade 0: didn't have it at all; Grade 1: noticed it, but it didn't interfere with usual activities at all; Grade 2: had it, and it was bad enough to prevent a significant part of usual activities; and Grade 3: had it, and it prevented most or all of normal activities, or had to see a doctor for prescription medicine. Participants with multiple symptoms in the same category were counted once per category using the symptom with the maximum grade.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2238","spread":null},{"groupId":"OG001","value":"2188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1932","spread":null},{"groupId":"OG001","value":"1898","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null},{"groupId":"OG001","value":"256","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2202","spread":null},{"groupId":"OG001","value":"2160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2183","spread":null},{"groupId":"OG001","value":"2148","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2033","spread":null},{"groupId":"OG001","value":"2077","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"124","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1923","spread":null},{"groupId":"OG001","value":"1877","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"264","spread":null},{"groupId":"OG001","value":"273","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2143","spread":null},{"groupId":"OG001","value":"2122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null},{"groupId":"OG001","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Unsolicited Adverse Events","description":"An AE was defined as any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a study vaccine, whether or not considered to be related to the study vaccine. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination, ascertained during follow-up visit or telephone contact up to (and including) the Day 28 contact, whether reported spontaneously by the participant or in response to general questions about current or interim health status.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61","spread":null},{"groupId":"OG001","value":"67","spread":null}]}]}]},{"type":"PRIMARY","title":"Lot Consistency: Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies Following FluBlok Vaccination","description":"GMTs of anti-influenza antibodies were measured using a single radial immunodiffusion (SRID) assay for 3 strains: A/Solomon Islands \\[H1N1\\], A/Wisconsin \\[H3N2\\], and B/Malaysia. Titers were expressed in terms of 1/dilution.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"346.15","spread":null},{"groupId":"OG001","value":"322.95","spread":null},{"groupId":"OG002","value":"381.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"390.34","spread":null},{"groupId":"OG001","value":"192.25","spread":null},{"groupId":"OG002","value":"240.01","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"182.10","spread":null},{"groupId":"OG001","value":"205.95","spread":null},{"groupId":"OG002","value":"215.34","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Positive Cell Culture/Culture-Confirmed Influenza Like Illness as Defined by Centers for Disease Control and Prevention (CDC-ILI)","description":"CDC-defined ILI was defined as fever (body temperature \\>=100ºF oral accompanied by cough and/or sore throat, on the same day or on consecutive days) due to strains represented in the vaccine.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroprotection to Influenza Vaccine Antigens After Vaccination With FluBlok","description":"Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \\[H1N1\\], A/Wisconsin \\[H3N2\\] and B/Malaysia. Seroprotection was defined as a post-vaccination HAI antibody titer of \\>=1:40.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion to Influenza Vaccine Antigens After Vaccination With FluBlok","description":"Anti-influenza antibodies were measured using an HAI assay for 3 strains: A/Solomon Islands \\[H1N1\\], A/Wisconsin \\[H3N2\\] and B/Malaysia. Seroconversion was defined as a post-vaccination titer of \\>=1:40 in participants with undetectable baseline antibody (HI titer = \\<1:10) or a \\>=4-fold rise in antibody in participants with a baseline titer of \\>=1:10, with the achievement of post-vaccination titer of at least 1:40.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":30,"n":2344},"commonTop":["Pharyngolaryngeal pain","Cough","Headache","Nasal congestion"]}}}